Psychiatric disorders are highly prevalent, often devastating diseases that negatively impact
the lives of millions of people worldwide. Although their etiological and diagnostic …

Acute administration of (R, S)-ketamine (ketamine) produces rapid antidepressant effects
that in some patients can be sustained for several days to more than a week. Ketamine …

Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …

Ketamine may have antidepressant properties, but its acute psychoactive effects complicate
successful masking in placebo-controlled trials. Here we present a single-center, parallel …

One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

The neurobiology of the psychedelic experience is not fully understood. Identifying common
brain network changes induced by both classical (ie, acting at the 5-HT 2 receptor) and non …

Serotonin reuptake inhibitor (SRI) medications are well established as first-line
pharmacotherapeutic treatment for Obsessive-Compulsive Disorder (OCD). However …

The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

In a subset of patients, chronic exposure to stress is an etiological risk factor for
neuroinflammation and depression. Neuroinflammation affects up to 27% of patients with …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …